Results 241 to 250 of about 1,949,102 (353)
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Priced Out of Treatment: The Exorbitant Cost of Antiparasitic Drugs in the United States. [PDF]
Alperin C, Nguyen N, Duffey M, Clark EH.
europepmc +1 more source
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
EVALUATION OF SYNERGISTIC ACTIVITY OF LAMIACEAE ESSENTIAL OILS WITH ANTIFUNGAL DRUGS AGAINST C. ALBICANS BY TRACKING THE DYNAMICS OF MICROBIAL DENSITY IN SUSPENSION [PDF]
NELI ERMENLIEVA
openalex +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Are drugs for rare diseases "essential"?
Marcus M Reidenberg
doaj
Evaluation of Prescription Practices Using WHO/INRUD Indicators and Determinants of Polypharmacy at a Kenyan County Referral Hospital. [PDF]
Kayioni J +3 more
europepmc +1 more source

